361 Capital’s Corcept Therapeutics CORT Stock Holding History

361 Capital’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-107,073	Closed	-$1.68M	–	341
2018 Q2	$1.68M	Buy	107,073 +9,789	+10%	+$170K	0.38%	106
2018 Q1	$1.6M	Buy	+97,284	New	+$1.8M	0.4%	80
2017 Q4	–	Sell	-115,429	Closed	-$2.23M	–	247
2017 Q3	$2.23M	Buy	115,429 +79,161	+218%	+$1.18M	0.43%	96
2017 Q2	$428K	Buy	+36,268	New	+$394K	0.07%	143

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

361 Capital's CORT Position: Q3 2018 in Review

361 Capital sold out of Corcept Therapeutics (CORT) in Q3 2018, closing a stake of 107,073 shares — an estimated $1.68M sold.

361 Capital first reported a position in CORT in Q2 2017 and held it in 4 quarters. The position peaked at $2.23M in Q3 2017. 207 funds tracked by Wall St. Rank hold CORT as of Q3 2018.

361 Capital reported no remaining Corcept Therapeutics position as of Q3 2018 after selling out during the quarter.
361 Capital sold 107,073 Corcept Therapeutics shares in Q3 2018, an estimated $1.68M.
361 Capital first reported a position in Corcept Therapeutics in Q2 2017 and held it in 4 quarters.
361 Capital's Corcept Therapeutics position peaked at $2.23M in Q3 2017.
207 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2018.

Based on 361 Capital's 13F filing for Q3 2018, filed 13 Nov 2018.